# 2026-12843: Government Selling Special Human Cell Line for Virus Research

2026-12843, Government Owned Inventions Available for License: C8166-45 Cell Line, is a Federal Register notice from Health and Human Services Department, National Institutes of Health published 2026-06-25, effective 2026-06-25; PRIA reads it as touching household money (as of 2026-07-02).

- Canonical: https://policyrisk.com/federal-register/2026-12843
- As of: 2026-07-02
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-12843
- Title: Government Owned Inventions Available for License: C8166-45 Cell Line
- Type: Notice
- Agencies: Health and Human Services Department; National Institutes of Health
- Citation: 91 FR 38452
- Published: 2026-06-25
- Effective: 2026-06-25
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-07-02

## In one line

Government Selling Special Human Cell Line for Virus Research

## Summary

The National Cancer Institute is offering a special human T-cell line called C8166-45 for licensing. This cell line helps scientists study viruses like HTLV-1 and HIV, which can cause serious diseases. Researchers and companies can now use this tool to develop better treatments, with licensing info available starting June 2026—no patents, just pure science power ready to roll!

## Abstract

The National Cancer Institute (NCI) seeks licensees for a human T-cell line, C8166-45, transformed by HTLV-1. C8166-45, also known as C63/CRII-2, contains three transcriptionally active proviruses useful for testing biological activities involved in T-cell immortalization and growth.

## Effects PRIA read

- C8166-45 Available for Licensing: benefit, medium. The National Cancer Institute is offering the human T‑cell line C8166-45 (NIH Reference Number E-272-2007) for non-exclusive licensing. The product is fully developed, listed as Research Material/Tool, and Patents: N/A; inquiries are directed to Diptadip Dattaroy, Ph.D., phone 240-276-7092 (Dated:…
- Tool for Gene Therapy Safety Testing: benefit, medium. The C8166-45 cell line is highly permissive to HIV-1 infection and is characterized as suitable for replication-competent lentiviral (RCL) assays to assess safety of gene therapy products such as lentiviral vectors. NCI highlights its use for studying HTLV-1 and HIV biology and for testing RCL assa…

## Related documents

- [2026-20771](https://policyrisk.com/federal-register/2026-20771): Center for Scientific Review; Notice of Closed Meetings, 2026-10-09
- [2026-20705](https://policyrisk.com/federal-register/2026-20705): Prospective Grant of Exclusive License, Inter-Institutional Agreement-Institution Lead: Antibody Specifically Binding to Severe Fever With…, 2026-10-09
- [2026-20424](https://policyrisk.com/federal-register/2026-20424): National Cancer Institute; Notice of Meeting, 2026-10-06
- [2026-20365](https://policyrisk.com/federal-register/2026-20365): Center For Scientific Review; Notice of Closed Meetings, 2026-10-05
- [2026-20151](https://policyrisk.com/federal-register/2026-20151): Notice of NIH Tribal Consultations and Listening Session, 2026-10-01
- [2026-19719](https://policyrisk.com/federal-register/2026-19719): Center for Scientific Review; Amended Notice of Meeting, 2026-09-28

## Sources
- [2026-12843 on federalregister.gov](https://www.federalregister.gov/documents/2026/06/25/2026-12843/government-owned-inventions-available-for-license-c8166-45-cell-line)
- [2026-12843 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-06-25/pdf/2026-12843.pdf)

## Related
- [Previous: 2026-12842, Government Owned Inventions Available for License: Compositions and Methods for…](https://policyrisk.com/federal-register/2026-12842)
- [Next: 2026-12844, Center for Scientific Review; Notice of Closed Meetings](https://policyrisk.com/federal-register/2026-12844)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-12843 (as of 2026-07-02).